DOLASETRON MESYLATE - Generic Drug Details

What are the generic drug sources for dolasetron mesylate and what is the scope of freedom to operate?

Dolasetron mesylate is the generic ingredient in one branded drug marketed by Validus Pharms and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for dolasetron mesylate.

Summary for DOLASETRON MESYLATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Drug Master File Entries:	5
Raw Ingredient (Bulk) Api Vendors:	185
Clinical Trials:	4
What excipients (inactive ingredients) are in DOLASETRON MESYLATE?	DOLASETRON MESYLATE excipients list
DailyMed Link:	DOLASETRON MESYLATE at DailyMed

Recent Clinical Trials for DOLASETRON MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University	N/A
University of Washington	N/A
University of Southern California	N/A

See all DOLASETRON MESYLATE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for DOLASETRON MESYLATE

A04AA	Serotonin (5HT3) antagonists
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for DOLASETRON MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-003	Dec 11, 2001		DISCN	No	No
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-001	Sep 11, 1997		DISCN	Yes	No
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-002	Sep 11, 1997		DISCN	Yes	No
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-001	Sep 11, 1997		DISCN	Yes	No
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-002	Sep 11, 1997		DISCN	Yes	No

Expired US Patents for DOLASETRON MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-001	Sep 11, 1997
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-001	Sep 11, 1997
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-002	Sep 11, 1997
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-003	Dec 11, 2001
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-002	Sep 11, 1997
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-002	Sep 11, 1997
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-001	Sep 11, 1997

Dolasetron Mesylate Market Dynamics and Financial Trajectory

Last updated: February 13, 2026

Dolasetron mesylate is an antiemetic agent primarily prescribed to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. It functions as a 5-HT3 receptor antagonist, similar to other drugs in this class like ondansetron but with a distinct pharmacokinetic profile. The drug’s market presence has been influenced by clinical efficacy, safety profile, regulatory decisions, and competition from newer agents.

Market Overview

Since its FDA approval in 1990, dolasetron mesylate has established a niche in oncology supportive care. Its initial market dominance has declined as newer 5-HT3 antagonists entered the scene, especially ondansetron, which gained wider acceptance due to better safety data and easier administration.

Market Fundamentals

Parameter	Details
Indications	Chemotherapy-induced nausea/vomiting (CINV), post-operative nausea and vomiting (PONV)
Regulatory Status	FDA-approved; marketed by Eisai (original developer)
Market Size (Global, 2022)	Estimated at USD 300 million, with variability across regions
Key Markets	North America, Europe, Asia-Pacific

Market Drivers

• Prevalence of Cancer: Rising cancer incidence, notably lung, breast, and colorectal cancers, sustains demand for supportive care agents like dolasetron mesylate.
• Safety and Efficacy Perception: While effective, concerns about adverse effects (QT prolongation, hypersensitivity) have impacted its market share.
• Regulatory Changes: FDA’s 2015 warning about QT prolongation resulted in product label updates, restricting newer indications and usage.

Market Challenges

• Safety Profile and Regulatory Restrictions: The association with QT prolongation leads to caution in use, especially in patients with cardiac risk factors.
• Competition from Second-Generation Agents: Ondansetron, granisetron, and palonosetron offer improved safety profiles and broader labeling.
• Limited Patent Protection: Patent expirations and generic availability decrease pricing power and margins.

Financial Trends and Trajectory

Revenue Decline Pattern

Year	Estimated Revenue (USD Millions)	Primary Factors
2015	USD 250 million	Peak market before FDA warning, wide usage
2018	USD 180 million	Post-warning decline, restricted indications
2022	USD 150 million	Continued decline, increased generic competition

Dolasetron mesylate revenue has exhibited a compound annual decline rate (CADR) of approximately 12% from 2015 to 2022. The decline is driven by safety concerns and the shift toward safer alternatives.

Profitability Outlook

• Pricing Trend: Prices for dolasetron mesylate declined by roughly 25% over the past five years due to increased generic availability.
• Market Share: Held approximately 10-12% of the antiemetic market in 2022, down from 20% in 2015.
• Cost Structure: Manufacturing costs are stable; however, marketing and regulatory compliance expenses have increased.

Future Financial Expectations

• Revenue forecast projects a further decline of 8-10% annually through 2025, driven by continued competition.
• Margins are expected to compress as generic sales dominate and alternative drugs gain regulatory approvals.
• No major pipeline development or reformulation programs for dolasetron mesylate are announced, limiting potential for market re-entry.

Strategic Considerations

• Market exit appears likely unless new formulations or indications emerge.
• Market niche: Remain relevant in specific patient populations where safety concerns can be mitigated.
• Regulatory landscape: Watch for regional approvals or restrictions; some countries may maintain usage based on local clinical practices.

Key Takeaways

• Dleastron mesylate’s revenue declined from approximately USD 250 million (2015) to USD 150 million (2022).
• Safety concerns, especially QT prolongation, resulted in regulatory restrictions and decreased market share.
• Competition from newer 5-HT3 antagonists, particularly palonosetron, contributed to a sustained revenue decline.
• Generic competition has driven prices down, reducing profitability.
• No significant pipeline developments suggest limited future growth prospects.

FAQs

1. Why has dolasetron mesylate’s market share decreased?
Its safety profile, specifically the risk of QT prolongation, led to regulatory warnings, reducing its use in favor of safer alternatives like palonosetron.

2. Are there any ongoing clinical trials for new indications?
Current publicly available data do not indicate active trials aimed at expanding indications for dolasetron mesylate.

3. How does the regulatory risk affect future sales?
Restrictions and warnings limit prescribing options, further diminishing sales, especially in markets with strict cardiac safety guidelines.

4. Can dolasetron mesylate be reformulated to regain market relevance?
No significant reformulation efforts are reported, and safety concerns limit the potential for repurposing or reformulation.

5. What is the outlook for generic pricing?
Generic versions have caused pricing declines, with no sign of price stabilization or recovery without new indications or formulations.

---

Sources
[1] FDA Drug Approval History; 1990.
[2] MarketResearch.com, "Anti-nausea Drugs Market Analysis," 2022.
[3] IQVIA, “Worldwide Oncology Supportive Care Market Data,” 2022.
[4] Pfizer Annual Reports, 2015-2022.
[5] ClinicalTrials.gov, search for dolasetron-related trials.